Examining the Impact of Darolutamide on Pain and QoL in Patients With Nonmetastatic CRPC

Training at a major academic center offers firsthand exposure to groundbreaking 177Lu-PSMA-617 treatment for advanced prostate cancer.

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

Those with metastatic castration-resistant prostate cancer in the BRCA subgroup experienced worse outcomes vs those in non-BRCA subgroups, according to the results of the CAPTURE trial.

In season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, delves into the critical topic of prostate cancer screening and discusses some of the recent advancements in the prostate cancer space.

Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.

Non-muscle invasive bladder cancer treatment with TAR-210 demonstrated safety and clinical activity in FGFR-altered high- and intermediate-risk patient groups.